AWARD
A -- RECOVERY- Operation of a Facility for the Study of Influenza Viruses, Vaccines and Antimicrobials in Human Subjects
- Notice Date
- 11/24/2009
- Notice Type
- Award Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive, Suite 2NE70, MSC 4811, Bethesda, Maryland, 20817
- ZIP Code
- 20817
- Solicitation Number
- HHSN272200900026C-1
- Point of Contact
- Alexander Kramer, Phone: 301-402-6835
- E-Mail Address
-
kramera@niaid.nih.gov
(kramera@niaid.nih.gov)
- Small Business Set-Aside
- N/A
- Award Number
- HHSN272200900026C-1
- Award Date
- 11/24/2009
- Awardee
- The University of Rochester (DUNS: 041294109), 601 Elmwood Avenue, Rochester, New York 14642, United States
- Award Amount
- $2,232,889
- Description
- This award consists of a modification to contract HHSN272200900026C. The purpose of this contract is to provide the full complement of services required, including volunteers, qualified personnel, material, equipment and facilities in which to study the biology of influenza viruses in humans, to examine the host's immune response to these viruses, and to test and evaluate new candidate vaccines for safety, genetic stability, immunogenicity, transmissibility and protective efficacy in humans. Studies will also include the safe administration of wild-type virus to healthy adult volunteers in order to assess pathogenicity, virulence and their suitability for use as a challenge virus in efficacy studies. These wild-type viruses will be used to challenge vaccinated adult volunteers in order to assess the extent of immunity induced by candidate vaccines. Studies will include both adult and pediatric subjects since influenza viruses cause severe respiratory disease in people of all ages. In summary, the requirement is to provide the necessary populations to study the biology and immunology of a variety of influenza viruses and serve as a testing center for the development of new vaccines effective against these agents. This modification will facilitate the initiation of H1N1 related studies under the contract. Rationale for not using a fixed price contract: A fixed price mechanism is not appropriate for this requirement. Although certain elements of the requirement, such as equipment and subcontracts, can and will be procured on a fixed price basis, the complexities of conducting clinical research are highly variable and dependent on too many external factors to accurately develop a fixed price estimate. Testing, patient care, and administrative costs can fluctuate greatly depending on the number of patients screened and participating in the studies conducted. Overall, the level of risk and number of uncertainties make a fixed price contract impractical and likely less cost effective than a cost-type arrangement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/AMOB/Awards/HHSN272200900026C-1.html)
- Record
- SN02010230-W 20091126/091124234813-7343179d310b41fb7177e689414b02d1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |